S1P receptor modulation (lymphocyte trafficking): slow disability worsening in relapsing MS · MSFrontier

No clear answer

relapsing MS · S1P receptor modulation (lymphocyte trafficking)

Trials have tried this, but none was a controlled phase 2 or 3 trial with a readable result.

Trials: 13
Running now: 0
Controlled phase 2/3 trials: 0
People in controlled trials: 0

No controlled trial has reported a result yet.

Other linked trials: 13

Dose comparisons, trials against another medicine, add-on trials, phase 1 and uncontrolled studies. They are listed below but do not set the status.

Trials

Other linked trials: 13

These linked trials do not set the status.

Assessing the Cognitive Benefits of Ozanimod and Their Brain-Biomarkers in MSStopped, other reason
Phase 4 · 2024 · Not randomised
OMNIAOMSStopped, other reason
Phase 4 · 2023 · Not randomised
FLUENTNo result found
Phase 4 · 2017 · Not randomised
Follow up Study of Patients on Fingolimod Who Were Enrolled in the Original Biobank Study (CFTY720DDE01)Met main goal
Phase 4 · 2016 · Not randomised
Effect of Fingolimod on NeurodegenerationStopped, other reason
Phase 4 · 2016 · Not randomised
ACROSSNo result found
Phase 4 · 2014 · Not randomised
BiobankIIStopped, other reason
Phase 4 · 2013 · Not randomised
CognitionMissed main goal
Phase 4 · 2011 · Compared with interferon beta-1b
BiobankNo result found
Phase 4 · 2011 · Not randomised
ENLIGHTENStopped, other reason
Phase 3 · 2020 · Not randomised

The deciding phase and counts come from the Trial Bank’s fixed rules.

Lab evidence

Lab studies in animals or cells. Results in animals often do not hold in people, and these studies never change the status of an idea.

Loading lab studies…

Loading reviews and guidelines…

History

2026-10-27First listed as No clear answer

Related hypotheses

Assembled by software from public sources and not checked by people. Each record links to its source. Report an error